Nightingale Health Ltd. is a Finnish biomedical science company, transforming chronic disease and population health research through use of its cutting edge NMR-based metabolomics platform. By providing comprehensive metabolic profiling of serum/plasma samples, Nightingale’s mission is to further molecular understanding and risk prediction of metabolic diseases. Our clientele consists of highly-esteemed medical universities & institutions and there are currently over 100 scientific publications that have successfully applied Nightingale’s method, including significant large-scale metabolomics and epidemiological studies. To date more than 500,000 samples have been analyzed using our biomarker platform, including the world's largest metabolomics project with 50 000 clinical trial samples for University of Cambridge and recently Nightingale's platform was installed to Oxford University’s clinical trial unit.
Nightingale’s biomarker analysis quantifies over 220 metabolic biomarker measures per blood sample in a single and affordable experiment. Amino acids, fatty acids, glycolysis metabolites, and lipoprotein subclasses are obtained simultaneously along with routine clinical lipid measures. Nightingale’s platform also scales to any number of samples and provides fast delivery times.
Blood metabolites are quantified in absolute concentrations (e.g. mmol/l) and can be analyzed in the same way as other clinical chemistry data. The fully automated NMR-based biomarker quantification provides superior repeatability (CV%) compared to mass spectrometry methods and is coupled with automated quality control.
By measuring biomarkers from multiple pathways in one go, Nightingale’s analysis delivers a fine-grained snapshot of systemic metabolism – providing novel molecular insights into the effects of lifestyle factors and genetic makeup on future disease risk. Nightingale’s biomarker analysis has been used to uncover novel biomarkers and improve the prediction of cardiovascular disease and type 2 diabetes. Detailed metabolic profiling also facilitates the study of molecular signatures for established risk factors and the effects of dietary and drug interventions.
Nightingale’s background is in academia and its team comprises of experts in computational medicine, NMR metabolomics and molecular epidemiology. Nightingale’s science department is led by Dr. Peter Würtz, an internationally recognized leader in the field of molecular epidemiology and Academy Research Fellow at University of Helsinki. Dr. Würtz’s research focuses on the applications of metabolomics in large population studies on cardiometabolic diseases, with the aims of improved prevention and enhanced understanding of disease mechanisms. As a part of Nightingale’s service, Dr. Würtz and his team also support customers in interpreting their results.
Please see "Biomarkers List" file on the left in Resources for full list of biomarkers.
Nightingale's metabolomics platform provides a fine-grained snapshot of systemic metabolism. By measuring over 220 biomarkers from multiple biological pathways in one go, we provide novel molecular insights into the effects of lifestyle factors, genetic makeup and future disease risk. Amino acids, fatty acids, glycolysis metabolites and lipoprotein subclasses are all obtained simultaneously with routine clinical lipid measures. Please see the 'Resources' for detailed biomarker listing.
Nightingale’s NMR-based biomarker analysis has been used to uncover novel biomarkers and to improve the prediction of cardiovascular disease, type 2 diabetes and many other chronic diseases. Our detailed metabolic profiling also enables the study of molecular signatures for established risk factors, as well as the effects of dietary and drug interventions.
• 220 biomarkers per plasma/serum sample - 350ul or 100ul sample size
• Data provided in quantitative measures (xlsx format) allowing study replication and statistical analyses
• No batch effects between sample sets across different time points
• Results review call with Nightingale's internal scientific team (optional to customer)
• Fast results delivery and competitive pricing based on order volume – e.g. 5,000 samples (350ul) analysed in 1 month at 28 euros per sample
Human blood sample quality control for biodegradation, batch effects from sample handling & interfering foreign substances. Feature of our biomarker analysis service can be utilised by biorepository to ensure quality of the blood sample collection to produce reliable &reproducible research results. Please see "Resources" files on the left side for more information.
Nightingale Health Ltd. has not received any reviews.
Nightingale Health Ltd. has not received any endorsements.